Incyte Analyst Ratings
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Gilead Sciences Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Natera Analysts Increase Their Forecasts Following Upbeat Results
10 Health Care Stocks With Whale Alerts In Today's Session
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Market-Moving News for November 13th
Baird Maintains Outperform on Natera, Raises Price Target to $160
Natera Analyst Ratings
Viking Therapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024
Natera Sees FY24 SG&A $775M-$825M; R&D $375M-$400M' Net Cash Inflows $50M-$75M.
Natera Sees FY24 Revenue $1.61B-$1.64B Vs $1.518B Est
Natera Q3 2024 GAAP EPS $(0.26) Beats $(0.58) Estimate, Sales $439.800M Beat $361.450M Estimate
ARKK's Holdings Ranked by SA Quant Grades
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Chevron, Super Micro Computer Top List of Most Shorted Large-cap Stocks in October, Hazeltree Says
Alnylam Downgraded at Wolfe on Doubts Over Amvuttra Growth